Project Grant P30AG102673
- The National Institute on Aging, part of the Department of Health and Human Services, awarded the University of California, Los Angeles $146,750 under the Aging Research program (CFDA 93.866) on July 1, 2026, to identify molecular-neuropathological signatures in Alzheimer's disease, frontotemporal lobar degeneration, and long COVID. The recipient will employ single-cell spatial multi-omics on postmortem brain tissues to characterize molecular and cellular alterations linked to selective...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of California, Los Angeles $244,897 on August 18, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop and validate AI approaches that enhance transparency and clinical generalizability of foundation models in radiology imaging diagnostics. The project focuses on lung disease detection on chest X-rays using two specific...
- The National Institute on Aging awarded The Leland Stanford Junior University $4.891 million on August 15, 2026, under the Aging Research program (CFDA 93.866) to establish the Stanford University Artificial Intelligence and Technology Collaboratory (SU-AITC) Center for Precision Health & Interventions in Aging and AD/ADRD. The award funds the development and deployment of artificial intelligence algorithms, scalable digital biomarkers, and cost-effective digital interventions to translate...
- The National Institute on Aging awarded $1,283,632 to the University of California, Los Angeles on September 30, 2025, under the Aging Research program (CFDA 93.866) to conduct the TARDIS-AD Project, a comparative and cost-effectiveness study of personalized targeted multifactorial approaches to reducing disparities in Alzheimer's disease and related dementias. The research leverages causal mediation, machine learning, and simulation modeling to identify personalized intervention strategies that...
- The National Institute on Aging awarded Duke University $4.899 million on August 15, 2026, under the Aging Research program (CFDA 93.866) to establish the Duke Artificial Intelligence and Technology Collaboratory for Aging: Governance and Evaluation (DUKE AITC-AIGE), a national initiative bridging the implementation gap between artificial intelligence research and its application in care for older adults and individuals with Alzheimer's disease and related dementias. The collaboratory operates...
- The National Institute on Aging awarded the University of California, Los Angeles $534,287 on September 30, 2025, under the Aging Research program (CFDA 93.866) to develop the CONNECT-AD Study, a multisite investigation of electronic health record communication networks in Alzheimer's disease and related dementia care teams. The study uses social network analysis, machine learning-assisted visual analytics, and qualitative methods to analyze EHR communication structure data across three...
- The National Institute on Aging awarded University of California, San Diego $165,488 on March 1, 2026, under the Aging Research program (CFDA 93.866) to reduce misdiagnosis in Alzheimer's disease through artificial intelligence-driven biomarker identification. The project constructs a comprehensive multidimensional database by repurposing over 1,500 limited-volume dementia samples using Silver-Seq, a small input liquid volume extracellular RNA sequencing technique, spanning 25 years of diverse...
- The National Institute on Aging awarded the University of California, Los Angeles $623,176 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research on modifiable risk factors for Alzheimer's disease and related dementias among individuals aged 90 and older. The research triangulates evidence across four data sources—the LifeAfter90 Study (1,397 participants, all aged 90), the 90+ Study (1,630 participants, all aged 90), the Health and Retirement Study (3,359...
- The University of California, Los Angeles received a $2.7 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 1, 2025, with completion scheduled for August 31, 2029. This research project will generate rigorous evidence comparing health outcomes for older patients with Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) who are discharged from hospitals to home-based care versus facility-based...
- The National Institute on Aging awarded the University of California, Berkeley $549,260 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop advanced large language model-based AI tools that enhance precision in predicting Alzheimer's disease pathology and cognitive outcomes. The research addresses critical gaps in precision medicine for Alzheimer's disease, particularly the need to capture patient heterogeneity, accurately identify treatment candidates for...
The National Institutes of Health Office of the Director awarded the University of California, Los Angeles $200,000 on July 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to establish governance and infrastructure for rapid, reproducible evaluation of artificial intelligence tools developed for Alzheimer's disease and related dementias populations. UCLA will develop the APEX-ADRD (Accelerating Platforms for Evaluating and Executing AI Lifecycles in ADRD) collaboratory, a national resource designed to accelerate responsible AI development and deployment across the NIA stage model (stages 0–V) by compressing validation timelines from years to months while preserving rigor, safety, and fairness. The collaboratory will operate through three core functions: building governance and evaluation infrastructure; catalyzing innovation via design studios that embed co-design and ethics principles early in the development process with access to unique data resources; and establishing best practices for ethical and fair AI including continuous post-deployment fairness monitoring. Work will be performed in Los Angeles, California, with a period of performance extending from July 1, 2026, through July 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/25/26 | ||
| Not listed | $100.0k | 8/7/26 |